IL194762D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
IL194762D0
IL194762D0 IL194762A IL19476208A IL194762D0 IL 194762 D0 IL194762 D0 IL 194762D0 IL 194762 A IL194762 A IL 194762A IL 19476208 A IL19476208 A IL 19476208A IL 194762 D0 IL194762 D0 IL 194762D0
Authority
IL
Israel
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Application number
IL194762A
Other versions
IL194762A (en
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US79504806P priority Critical
Priority to PCT/US2007/009866 priority patent/WO2007127175A2/en
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of IL194762D0 publication Critical patent/IL194762D0/en
Publication of IL194762A publication Critical patent/IL194762A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
IL194762A 2006-04-26 2008-10-22 4-morpholino-thienopyrimidine derivatives, process for their preparation and pharmaceutical compositions comprising them for treating diseases or disorders IL194762A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US79504806P true 2006-04-26 2006-04-26
PCT/US2007/009866 WO2007127175A2 (en) 2006-04-26 2007-04-24 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
IL194762D0 true IL194762D0 (en) 2009-08-03
IL194762A IL194762A (en) 2014-09-30

Family

ID=38606432

Family Applications (1)

Application Number Title Priority Date Filing Date
IL194762A IL194762A (en) 2006-04-26 2008-10-22 4-morpholino-thienopyrimidine derivatives, process for their preparation and pharmaceutical compositions comprising them for treating diseases or disorders

Country Status (23)

Country Link
US (2) US8802670B2 (en)
EP (2) EP2041139B1 (en)
JP (1) JP5546240B2 (en)
KR (1) KR101422301B1 (en)
CN (1) CN101479274B (en)
AR (1) AR060633A1 (en)
AT (1) AT532788T (en)
AU (1) AU2007243457B2 (en)
BR (1) BRPI0710943A2 (en)
CA (1) CA2650290C (en)
CL (1) CL2007001167A1 (en)
DK (1) DK2041139T3 (en)
ES (1) ES2377358T3 (en)
HK (1) HK1127356A1 (en)
IL (1) IL194762A (en)
MX (1) MX2008013584A (en)
NO (1) NO20084928L (en)
PL (1) PL2041139T3 (en)
PT (1) PT2041139E (en)
RU (1) RU2443706C2 (en)
TW (1) TWI498332B (en)
WO (1) WO2007127175A2 (en)
ZA (1) ZA200809546B (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010381A1 (en) * 1996-09-04 1998-03-12 Intertrust Technologies Corp. Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
RU2008141356A (en) 2006-04-26 2010-06-10 Ф. Хоффманн-Ля Рош Аг (Ch) Pyrimidine Derivatives as Phosphatidylinositol-3-Kinase Inhibitors (PI3K)
MX2008013584A (en) 2006-04-26 2009-03-23 Genentech Inc Pharmaceutical compounds.
WO2008070740A1 (en) 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
TW200829594A (en) * 2006-12-07 2008-07-16 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
CA2692050A1 (en) * 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
AR068402A1 (en) 2007-09-12 2009-11-18 Genentech Inc Combinations of inhibitor compounds phosphoinositide 3-kinase and chemotherapeutic agents and methods of use
ES2399774T3 (en) * 2007-09-24 2013-04-03 Genentech, Inc. Thiazolopyrimidine compounds PI3K inhibitors and methods of use
ES2439705T3 (en) * 2007-10-25 2014-01-24 Genentech, Inc. Process for the preparation of thienopyrimidine compounds
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
JP5638955B2 (en) * 2007-10-26 2014-12-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Purine derivatives useful as PI3 kinase inhibitors
GB0723748D0 (en) * 2007-12-04 2008-01-16 Ucb Pharma Sa Therapeutic agents
HUE035182T2 (en) * 2008-03-18 2018-05-02 Genentech Inc Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab
JP2011515462A (en) * 2008-03-27 2011-05-19 アウククランド ウニセルビセス リミテッド Substituted pyrimidines and triazines and their use in cancer therapy
WO2010002954A1 (en) * 2008-07-02 2010-01-07 Wyeth (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
CN102171194A (en) * 2008-07-31 2011-08-31 健泰科生物技术公司 Pyrimidine compounds, compositions and methods of use
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8653098B2 (en) * 2008-11-20 2014-02-18 Genentech, Inc. Pyrazolopyridine PI3K inhibitor compounds and methods of use
DK2385832T3 (en) * 2009-01-08 2015-09-21 Curis Inc Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel
KR101781654B1 (en) 2009-03-12 2017-09-25 제넨테크, 인크. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
ES2527046T3 (en) 2009-03-24 2015-01-19 Sumitomo Chemical Company, Limited Method for the preparation of a boronic acid ester compound
EP2411387B1 (en) 2009-03-27 2015-08-19 VetDC, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
JP5805623B2 (en) 2009-04-16 2015-11-04 フンダシオン セントロ ナシオナル デ インベスティガシオネス オンコロヒカス カルロス ザ サードFundacion Centro Nacional de Investigaciones Oncologicas Carlos III Imidazopyrazines for use as kinase inhibitors
US8158625B2 (en) * 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
CA2761445A1 (en) * 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
SG176959A1 (en) * 2009-06-24 2012-01-30 Genentech Inc Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
DK3072890T3 (en) * 2009-07-07 2019-02-11 Mei Pharma Inc Pyrimidinyl and 1,3,5-triazinylbenzimidazoles and their use in cancer therapy
AU2010276160A1 (en) 2009-07-21 2012-02-09 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
EP2475375A4 (en) * 2009-09-09 2013-02-20 Avila Therapeutics Inc Pi3 kinase inhibitors and uses thereof
JP2013505965A (en) * 2009-09-29 2013-02-21 エックスカバリー ホールディング カンパニー エルエルシー PI3K (delta) selective inhibitor
CA2780018C (en) * 2009-11-12 2015-10-20 F. Hoffmann-La Roche Ag N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
ES2596654T3 (en) * 2009-11-12 2017-01-11 F. Hoffmann-La Roche Ag N-9-substituted purine compounds, compositions and methods of use
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
KR101498774B1 (en) 2010-02-22 2015-03-04 에프. 호프만-라 로슈 아게 Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
EP2593455B1 (en) 2010-07-14 2015-03-18 F.Hoffmann-La Roche Ag Purine compounds selective for i3 p110 delta, and methods of use
US8551981B2 (en) * 2010-10-08 2013-10-08 Abbvie Inc. Furo[3,2-d]pyrimidine compounds
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
EP2651951B1 (en) 2010-12-16 2014-11-19 F.Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
EP2667874A4 (en) * 2011-01-27 2014-07-30 Univ Princeton Inhibitors of mtor kinasa as anti- viral agents
BR112013020329A2 (en) 2011-02-09 2016-08-02 Hoffmann La Roche heterocyclic compounds as pi3 kinase inhibitors
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
KR20140032383A (en) 2011-03-21 2014-03-14 에프. 호프만-라 로슈 아게 Benzoxazepin compounds selective for pi3k p110 delta and methods of use
TWI572599B (en) * 2011-03-28 2017-03-01 Mei製藥公司 (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
PT2694075T (en) * 2011-04-01 2016-07-11 Curis Inc Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2014001063A (en) 2011-07-28 2014-09-01 Genentech Inc Pik3ca h1047r knock-in non-human animal breast cancer model.
JP6206926B2 (en) 2011-11-23 2017-10-04 キャンサー・リサーチ・テクノロジー・リミテッド Thienopyrimidine inhibitor of abnormal protein kinase C
CN102643272B (en) * 2011-12-30 2015-03-11 沈阳药科大学 Novel thieno [3, 2-d] pyrimidine compound
US20170002313A1 (en) 2012-05-23 2017-01-05 Genentech Inc. Compositions and methods of obtaining and using endoderm and hepatocyte cells
JP5933830B2 (en) 2012-06-08 2016-06-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Variant selectivity and combination of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of cancer
US9359367B2 (en) 2012-07-09 2016-06-07 Lupin Limited Tetrahydroquinazolinone derivatives as PARP inhibitors
RU2612251C2 (en) * 2012-08-30 2017-03-03 Ф. Хоффманн-Ля Рош Аг Dioxino- and oxazin-[2,3-d]pyrimidine compounds as phosphoinositide 3-kinase inhibitors and methods for use thereof
MX349551B (en) 2012-10-10 2017-08-02 Hoffmann La Roche Process for making thienopyrimidine compounds.
US9745321B2 (en) 2013-09-30 2017-08-29 Shanghai Yingli Pharmaceutical Co., Ltd Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
TWI648281B (en) 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 Sulfur-containing bicyclic compound of formula
AR104068A1 (en) 2015-03-26 2017-06-21 F Hoffmann-La Roche Ag Combinations of a kinase inhibitor 3 and a compound of CDK4 / 6 for the treatment of cancer inhibitor compound phosphoinositide
US10174035B2 (en) 2015-03-30 2019-01-08 Daiichi Sankyo Company, Limited 6-morpholinyl-2-pyrazolyl-9H-purine derivatives and their use as PI3K inhibitors
US9938273B2 (en) * 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA3030021A1 (en) * 2016-07-07 2018-01-11 Cardurion Pharmaceuticals, Llc Methods for treatment of heart failure
TW201825465A (en) 2016-09-23 2018-07-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201813963A (en) 2016-09-23 2018-04-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201815787A (en) 2016-09-23 2018-05-01 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
WO2019193134A1 (en) 2018-04-06 2019-10-10 H. Lundbeck A/S Process for the preparation of 2,2-dimethylpiperazine

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4321M (en) * 1964-01-15
BE754606A (en) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K New 2-aminoalkylamino-thieno (3,2-d) pyrimidine and manufacturing procedesde
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE759493A (en) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K New 2- (5-nitro-2-furyl) thieno (3,2-d) pyrimidines and methods for making
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (en) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Process for the preparation of thyeno- (3,2-d) -pyrimidines
CH592668A5 (en) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4196207A (en) * 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
JPH08175990A (en) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Pi3 kinase-inhibiting agent and its production
JPH08176070A (en) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Didepside derivative and pi3 kinase inhibitor
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
DE69943144D1 (en) * 1998-03-31 2011-03-03 Kyowa Hakko Kirin Co Ltd Nitrogen-containing heterocyclic compounds
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2001247477A (en) 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd Antitumor medicine
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AT290882T (en) 2001-01-16 2005-04-15 Glaxo Group Ltd Pharmaceutical mixture against cancer containing a 4-chinazolinamine in combination with paclitaxel, carboplatin or vinorelbine
EP1417976A4 (en) 2001-07-26 2004-09-15 Santen Pharma Co Ltd Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect
US6703414B2 (en) 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
WO2003034997A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
AU2002349912A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
CA2464924A1 (en) 2001-10-30 2003-05-08 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
JP2006500327A (en) 2002-07-10 2006-01-05 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ Use of compounds to increase sperm motility
MXPA05000453A (en) 2002-07-10 2005-03-23 Applied Research Systems Azolidinone-vinyl fused-benzene derivatives.
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
MXPA05001808A (en) * 2002-09-30 2005-08-16 Bayer Pharmaceuticals Corp Fused azole-pyrimidine derivatives.
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
ES2217956B1 (en) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. New derivatives of 4-aminotiene (2,3-d) pirimidin-6-carbonitrile.
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US7781433B2 (en) * 2006-04-26 2010-08-24 Piramed Limited Pharmaceutical compounds
RU2008141356A (en) 2006-04-26 2010-06-10 Ф. Хоффманн-Ля Рош Аг (Ch) Pyrimidine Derivatives as Phosphatidylinositol-3-Kinase Inhibitors (PI3K)
MX2008013584A (en) 2006-04-26 2009-03-23 Genentech Inc Pharmaceutical compounds.
TW200801012A (en) * 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2008070740A1 (en) * 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use

Also Published As

Publication number Publication date
NO20084928L (en) 2009-01-26
CN101479274B (en) 2013-06-12
EP2041139A2 (en) 2009-04-01
US9943519B2 (en) 2018-04-17
ES2377358T3 (en) 2012-03-26
US8802670B2 (en) 2014-08-12
AU2007243457A1 (en) 2007-11-08
KR101422301B1 (en) 2014-07-30
AU2007243457B2 (en) 2012-02-23
PT2041139E (en) 2012-01-13
CN101479274A (en) 2009-07-08
HK1127356A1 (en) 2012-06-01
JP2009538825A (en) 2009-11-12
TWI498332B (en) 2015-09-01
TW200813069A (en) 2008-03-16
WO2007127175A2 (en) 2007-11-08
DK2041139T3 (en) 2012-01-16
AT532788T (en) 2011-11-15
RU2443706C2 (en) 2012-02-27
MX2008013584A (en) 2009-03-23
WO2007127175A3 (en) 2007-12-27
PL2041139T3 (en) 2012-05-31
US20140309216A1 (en) 2014-10-16
CL2007001167A1 (en) 2008-01-25
BRPI0710943A2 (en) 2012-06-26
US20080076758A1 (en) 2008-03-27
EP2041139B1 (en) 2011-11-09
ZA200809546B (en) 2010-04-28
CA2650290C (en) 2015-11-17
CA2650290A1 (en) 2007-11-08
JP5546240B2 (en) 2014-07-09
RU2008145660A (en) 2010-06-20
KR20090014283A (en) 2009-02-09
AR060633A1 (en) 2008-07-02
US20160152632A9 (en) 2016-06-02
EP2402347A1 (en) 2012-01-04
IL194762A (en) 2014-09-30

Similar Documents

Publication Publication Date Title
DK2041139T3 (en) pharmaceutical compounds
SI2004635T1 (en) Substituted enaminocarbonyl compounds
ZA200807383B (en) New compounds
ME01550B (en) Pharmaceutical dosage forms
EP2001498A4 (en) Pharmaceutical compositions
HK1173980A1 (en) Pharmaceutical compositions
IL194176D0 (en) Pharmaceutical compositions
IL194438D0 (en) Diarylthiohydantoin compounds
ZA201104336B (en) Pharmaceutical compounds
ZA200808530B (en) Pharmaceutical composition for external use
GB0608386D0 (en) Compounds
GB0501999D0 (en) Pharmaceutical compounds
GB0520657D0 (en) Pharmaceutical compounds
EP2005959A4 (en) External pharmaceutical composition
GB0608263D0 (en) Compounds
GB0709031D0 (en) Pharmaceutical compounds
ZA200808531B (en) Pharmaceutical composition for external use
GB0625322D0 (en) Pharmaceutical compositions
HK1123545A1 (en) Therapeutic compounds
GB0610680D0 (en) Therapeutic compounds
GB0602424D0 (en) Compounds
IL201366D0 (en) Pharmaceutical compounds
EP2191826A4 (en) Pharmaceutical composition
EP2133095A4 (en) Pharmaceutical composition
EP2133094A4 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees